Pharma Mar, S.A. Stock price

Equities

PHM

ES0169501022

Pharmaceuticals

Market Closed - BME 12:35:12 2024-03-28 pm EDT 5-day change 1st Jan Change
28.74 EUR +0.63% Intraday chart for Pharma Mar, S.A. 0.00% -30.04%
Sales 2024 * 171M 184M Sales 2025 * 200M 215M Capitalization 507M 547M
Net income 2024 * 5M 5.39M Net income 2025 * 56M 60.42M EV / Sales 2024 * 2.29 x
Net cash position 2024 * 116M 125M Net cash position 2025 * 193M 208M EV / Sales 2025 * 1.57 x
P/E ratio 2024 *
84.5 x
P/E ratio 2025 *
11.2 x
Employees 509
Yield 2024 *
2.26%
Yield 2025 *
1.71%
Free-Float 76.54%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.63%
Current month-5.46%
1 month-14.46%
3 months-32.44%
6 months-10.19%
Current year-30.04%
More quotes
1 week
27.70
Extreme 27.7
29.04
1 month
27.70
Extreme 27.7
31.78
Current year
27.70
Extreme 27.7
42.80
1 year
27.70
Extreme 27.7
45.00
3 years
27.70
Extreme 27.7
101.35
5 years
17.42
Extreme 17.424
148.00
10 years
10.45
Extreme 10.452
148.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 86-04-29
Director of Finance/CFO - 87-12-31
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chief Executive Officer - 86-04-29
Director/Board Member - 86-04-29
Director/Board Member - -
More insiders
Date Price Change Volume
24-03-28 28.74 +0.63% 37,220
24-03-27 28.56 +1.49% 45,156
24-03-26 28.14 +0.36% 32,659
24-03-25 28.04 -1.54% 35,438
24-03-22 28.48 -1.18% 53,021

Delayed Quote BME, March 28, 2024 at 12:35 pm EDT

More quotes
Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company's product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
28.74 EUR
Average target price
49.4 EUR
Spread / Average Target
+71.89%
Consensus
  1. Stock
  2. Equities
  3. Stock Pharma Mar, S.A. - BME